Outcome of transurethral plasmakinetic vaporization for benign prostatic hyperplasia

To assess the outcome of transurethral plasmakinetic vaporization (PKVP) in the management of benign prostatic hyperplasia (BPH).

From August 2010 to May 2012, 60 patients with obstructive LUTS due to BPH were included in the study. All patients were evaluated by International Prostate Symptom Score (IPSS), general examination, digital rectal examination, PSA, routine laboratory examinations, pelvi-abdominal ultrasound, trans-rectal ultrasound, and uroflowmetry. Patients with Qmax of <10 mL/sec., an IPSS of >8 and a prostate volume of >40 mL underwent transurethral PKVP.

Mean age of the patients was 66.8 ± 4.5 years. The mean times of the operation, post-operative bladder irrigation, and post-operative catheterization were 63.8 ± 13.9 minutes, 15.2 ± 5.7 hours, and 23.9 ± 5.2 hours, respectively. At 3 months of follow-up, there were significant reductions in the mean IPSS from 23.4 ± 3.5 to 9.2 ± 3.7 (P=0.4), mean PSA from 3.03 ± 2.2 ng/mL to 1.2 ± 1.04 ng/mL (P value=0.02), mean post voiding residual urine from 149.8 ± 59.5 mL to 46.9 ± 24.1 mL (P value <0.01), and mean prostate volume from 72.8 ± 10.3 mL to 22.7 ± 6.1 mL (P value <0.01). Also, there was a statistically significant increase in the mean Q max. from 8.7 ± 2.4 mL/s to 19.5 ± 3.5 mL/s (P value <0.01).

PKVP is an effective and safe treatment option in the management of symptomatic BPH.